Venous leg & pressure ulcers
Venous leg ulcers (VLUs) and pressure ulcers are chronic, hard-to-heal wounds whose stalled healing is driven largely by polymicrobial biofilms—dense, matrix-encased communities typically dominated by Pseudomonas aeruginosa, Staphylococcus aureus (often MRSA), Enterococcus, Klebsiella, and Escherichia coli. Biofilm cells tolerate antibiotics at 100–1000x the concentrations needed to kill planktonic bacteria, so systemic antibiotics penetrate poorly and select for resistance while the wound remains colonized. Bacteriophages are an attractive complement here because they are applied topically directly onto the wound bed, self-amplify wherever their host bacteria are present, encode depolymerases that degrade the biofilm exopolysaccharide matrix, and can be assembled into cocktails that cover the several pathogens found in a single polymicrobial ulcer. Critically, phages kill antibiotic-resistant strains by a mechanism orthogonal to antibiotics and can resensitize bacteria to drugs, making them well matched to these recalcitrant, frequently MDR wounds.
How phages act here
Mechanism
Lytic phages bind strain-specific surface receptors (LPS, teichoic acids, pili), inject their genome, hijack the host, and lyse the cell—so coverage is achieved by combining multiple phages into a cocktail spanning the key wound pathogens (P. aeruginosa, S. aureus, E. coli, Klebsiella, Enterococcus). Against the polymicrobial biofilm specifically, many wound phages carry depolymerase/EPS-degrading enzymes that breach the extracellular matrix, letting phages reach embedded and persister cells that antibiotics miss; progeny phages then propagate through the biofilm. Phage-antibiotic synergy (PAS) is well documented—sublethal antibiotic exposure boosts phage replication, and phage pressure can drive 'evolutionary trade-offs' that resensitize bacteria to antibiotics (e.g., loss of efflux or capsule). Delivery is increasingly engineered for the wound environment: impregnated biodegradable polymer matrices (PhagoBioDerm), encapsulated microcapsule sprays (BACTELIDE), and hydrogels protect phages and provide sustained release. Engineered/synthetic phages and CRISPR-Cas 'sequence-specific antimicrobials' are an active research angle to broaden host range and add anti-biofilm/anti-resistance payloads, though these remain preclinical for wounds.
Where it stands
Current evidence
Evidence is early-stage but directly on-target. The landmark indication-specific study is a 2009 FDA-cleared Phase I randomized, double-blind, controlled safety trial (WPP-201, an 8-phage cocktail vs P. aeruginosa, S. aureus, E. coli, by Intralytix) in 42 chronic venous leg ulcer patients (Rhoads, Wolcott et al.): no product-attributable adverse events, establishing safety but not powered for efficacy—no Phase II VLU efficacy trial has yet reported. Earlier, the Eliava-derived PhagoBioDerm sustained-release matrix (phages + ciprofloxacin) treated 107 patients with venous stasis/poorly-healing ulcers in Georgia (Markoishvili 2002), with complete healing in 70% of evaluable refractory cases. More recently, a 2024 randomized, placebo-controlled, double-blind RCT (Karn, Nath et al., Banaras Hindu University; n=60) of customized phage cocktails in chronic wounds—including MDR and biofilm-associated infections—reported 93.3% sterility by a median of 39 days and complete healing by 90 days vs persistent colonization in placebo. For pressure ulcers specifically, Precisio Biotix Therapeutics registered a Phase 1/2 trial (NCT04815798) of BACTELIDE, a 14-phage encapsulated spray targeting S. aureus, P. aeruginosa, and K. pneumoniae in Stage II–IV pressure injuries. Most use to date is via compassionate/magistral routes (Eliava Center, Georgia; Pyophage/Pyobacteriophage) and small surgical-wound RCTs; no phage product is yet licensed for these indications in the US or EU.
Evidence confidence: medium
The data
Key studies & trials
- Rhoads DD, Wolcott RD, Kuskowski MA, Wolcott BM, Ward LS, Sulakvelidze A. Bacteriophage therapy of venous leg ulcers in humans: results of a phase I safety trial. Journal of Wound Care. 2009 Jun;18(6):237-43. ↗
- Markoishvili K, Tsitlanadze G, Katsarava R, Morris JG Jr, Sulakvelidze A. A novel sustained-release matrix based on biodegradable poly(ester amide)s and impregnated with bacteriophages and an antibiotic shows promise in management of infected venous stasis ulcers and other poorly healing wounds. International Journal of Dermatology. 2002 Jul;41(7):453-8. ↗
- Karn SL, Bhartiya SK, Pratap A, Saroj SK, Kumar R, Sahu M, Gangwar M, Nath G. A Randomized, Placebo-controlled, Double-blind Clinical Trial of Bacteriophage Cocktails in Chronic Wound Infections. International Journal of Lower Extremity Wounds. 2024 (Epub 2024 Jan 17);25(2):427-437. ↗
- Precisio Biotix Therapeutics, Inc. A Randomized, Double-blind Study to Evaluate the Safety, Tolerability, and Potential Efficacy of BACTELIDE vs. Placebo in Addition to Standard-of-care for S. aureus, P. aeruginosa, and K. pneumoniae Colonized Pressure Injuries. ClinicalTrials.gov Identifier NCT04815798 (Phase 1/2). ↗
Who is working on it
Programs & centers
The possibility
As resistant biofilms keep millions of leg and pressure ulcers open for months, a personalized phage approach—swab the wound, match a cocktail to its specific P. aeruginosa and S. aureus strains, and spray or embed it in a slow-release dressing—could turn a stalled, antibiotic-refractory wound sterile within weeks while sparing the patient systemic drugs. Paired with depolymerase-armed and engineered phages that dissolve the matrix and resensitize bacteria to companion antibiotics, future 'living dressings' could be re-tuned in real time as the wound's microbial community shifts. With European Pharmacopoeia quality standards for phage medicines now in place, the missing piece is no longer plausibility but an adequately powered Phase II/III efficacy trial to move these cocktails from compassionate use into routine wound-care formularies.